These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12799573)

  • 1. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
    Moreno S; Casado JL; Pérez-Elías MJ; Dronda F; Antela A; Moreno A; Gutiérrez C
    AIDS; 2003 Jun; 17(9):1413-4. PubMed ID: 12799573
    [No Abstract]   [Full Text] [Related]  

  • 2. NNRTIs: a neglected class.
    Cadman J
    GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New reverse transcriptase inhibitors.
    Crowe S
    Adv Exp Med Biol; 1999; 458():183-97. PubMed ID: 10549391
    [No Abstract]   [Full Text] [Related]  

  • 5. What they say about: non-nucleoside drugs.
    Posit Aware; 2000; 11(1):44-7. PubMed ID: 11366350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
    Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
    AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitor-sparing regimens: new evidence strengthens position.
    Moyle GJ
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S17-25; quiz S26-8. PubMed ID: 12946062
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

  • 10. What they say about non-nucleoside drugs.
    Posit Aware; 1999; 10(1):35-7. PubMed ID: 11366521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz: resistance and cross-resistance.
    Clotet B
    Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Zhang Z; Hamatake R; Hong Z
    Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of NNRTIs in antiretroviral combination therapy: an introduction.
    Nelson M
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():1-2. PubMed ID: 11589821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
    Casado JL; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
    AIDS; 2000 Jan; 14(2):F1-7. PubMed ID: 10708276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CROI--presentation of new study results. In a comparison of NNRTI nevirapine is equally effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373068
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of NNRTIs in antiretroviral-experienced patients.
    Maggiolo F
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():10-7. PubMed ID: 11589823
    [No Abstract]   [Full Text] [Related]  

  • 19. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
    Moyle G
    Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.